The ongoing COVID-19 pandemic has forced the clinical and scientific community to try drug repurposing of existing antiviral agents as a quick option against SARS-CoV-2. Under this scenario, the interferon-β 1a (IFN-β 1a) whose antiviral potential is already known, and is a drug currently used in the clinical management of multiple sclerosis, may represent as a potential candidate. In this report, we demonstrate that IFN-β 1a was highly effective in inhibiting in vitro SARS-CoV-2 replication at clinically achievable concentration when administered after virus infection.

Interferon-β-1a inhibition of severe acute respiratory syndrome–Coronavirus 2 in vitro when administered after virus infection

Clementi M.;Mancini N.;
2020-01-01

Abstract

The ongoing COVID-19 pandemic has forced the clinical and scientific community to try drug repurposing of existing antiviral agents as a quick option against SARS-CoV-2. Under this scenario, the interferon-β 1a (IFN-β 1a) whose antiviral potential is already known, and is a drug currently used in the clinical management of multiple sclerosis, may represent as a potential candidate. In this report, we demonstrate that IFN-β 1a was highly effective in inhibiting in vitro SARS-CoV-2 replication at clinically achievable concentration when administered after virus infection.
2020
COVID-19 clinical trial; IFN-β 1a; SARS-CoV-2
Clementi, N.; Ferrarese, R.; Criscuolo, E.; Diotti, R. A.; Castelli, M.; Scagnolari, C.; Burioni, R.; Antonelli, G.; Clementi, M.; Mancini, N.; Criscuolo, Elena
File in questo prodotto:
File Dimensione Formato  
JID_jiaa350.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 401.31 kB
Formato Adobe PDF
401.31 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2149000
Citazioni
  • ???jsp.display-item.citation.pmc??? 44
  • Scopus 47
  • ???jsp.display-item.citation.isi??? 47
social impact